



Central European Urology Meeting 2022 (CEM22)

1st - 2nd April 2022
Vienna, Austria

Please register at our
Website www.uro-cem.com
or per Email to office@uro-cem.com

Hilton Vienna Danube Waterfront
Handelskai 269,
1020 Vienna

International Lecturers
Newest Therapies and Concepts
Innovation and Interaction

CEM22
Central European Meeting



COMPREHENSIVE CANCER CENTER VIENNA



MEDICAL UNIVERSITY
OF VIENNA



Vienna Healthcare Group
University Hospital Vienna



Friday, 1st April 2022

15:00 - 16:30

First Workshop

16:30 - 18:00

Second Workshop

18:00 - 18:15

Coffee break

Workshop 1

Case-based urologic reconstruction

Workshop Chair: P. Nyirady

Workshop Speakers: V. Kojić, S. Ahyai

Workshop 2

Case-based management of metastatic prostate cancer

Workshop Chair: G. Kramer

Workshop Speakers: M. Hassler, S. Korn

Workshop 3

Case-based management of advanced bladder cancer

Workshop Chair: K. Gust

Workshop Speakers: D. D'Andrea, A. Czech

Workshop 4

Case-based management of metastatic kidney cancer

Workshop Chair: M. Schmidinger

Workshop Speaker: D. Niedersüß-Beke, M. Seles

Workshop 5

Hands-on laparoscopy

Workshop Chair: H. Fajkovic

Workshop Tutors: M. Remzi, J. Dobruch, V. Novák, K. Gronostaj, D. Mun

Workshop 6

Semi-live stone surgery & hands-on endoscopy

Workshop Chair: C. Seitz

Workshop Tutors: J. Vesper,

V. Jahrreiss, M. Klitsch

Workshop 7

MRI and fusion biopsy for prostate cancer

Workshop Chair: N. Huebner

Workshop Tutors: P. Baltzer, P. Rajwa, A. Alimohammadi

18:15 - 20:00

Moderated poster session, 20 best posters

Chairs: S. Shariat (AT), H. Fajkovic (AT)

Judges: D. Bratus (SLO), P. Chlosta (PL),

M. Hora (CZ), S. Krause (AT),

O. Martha (RO), I. Minčík (SK),

P. Nyirady (HU), I. Tomašković (HR)

All submitted posters will be accepted and displayed. The 20 best posters will be invited for a moderated presentation.

The 3 best posters will be given an award (500 Euro).

Saturday, 2nd April 2022

08:00 - 08:30

Welcome and introduction

08:30 - 09:30

Bladder cancer

Chairs: M. Babjuk (CZ), S. Krause (AT)

08:30 - 08:45

Molecular classification of bladder cancer: the promised land?

A. Oszwald (AT)

08:45 - 09:00

Urothelial carcinoma 2022 – what is on the horizon?

J. Dobruch (PL)

09:00 - 09:30

Challenge the expert: The best management of clinically localized muscle invasive bladder cancer is ...

09:00 - 09:05

Case presentation

S. Broenimann (AT)

09:05 - 09:15

Bladder-sparing - the new standard

K. Gust (AT)

09:15 - 09:25

Radical cystectomy - it remains clearly superior

A. Czech (PL)

09:25 - 09:30

Discussion

09:30 - 10:30

Kidney and Adrenal cancers

Chairs: P. Chlosta (PL), H. Fajkovic (AT)

09:30 - 09:45

What is new for adrenal tumors?

M. Remzi (AT)

09:45 - 10:00

Cyto-reductive nephrectomy: defining its role today!

M. Hora (CZ)

10:00 - 10:30

Challenge the expert: First line for metastatic RCC should be...

10:00 - 10:05

Case presentation

A. Alimohammadi (AT)

10:05 - 10:15

IO/IO: the winner!

M. Schmidinger (AT)

10:15 - 10:25

IO/TKI – my first choice!

L. Torday (HU)

10:25 - 10:30

Discussion

10:30 - 10:45

Coffee break and poster viewing

10:45 - 12:15

ESU course: Prostate cancer

Treatment for biochemical recurrence (BCR) after local therapy and for oligometastatic disease

12:15 - 13:15

Lunch break and poster viewing

13:15 - 14:15

Urolithiasis

Chairs: I. Tomašković (HR),
S. Ahyai (AT)

13:15 - 13:30

Intelligent deployment of single use flexible scopes

I. Perečinsky (SK)

13:30 - 13:45

Technologic advances in endurology
C. Seitz (AT)

13:45 - 14:15

Challenge the expert: Should we treat 4mm residual fragments?

13:45 - 13:50

Case presentation

V. Jahrreis (AT)

13:50 - 14:00

Yes, leave no stone behind!

J. Veser (AT)

14:00 - 14:10

No, it is irrelevant!

A. Szendrői (HU)

14:10 - 14:15

Discussion

14:15 - 15:00

Voiding dysfunction

Chairs: D. Bratus (SLO),
Ivan Minčík (SK)

14:15 - 14:30

Management of OAB in frail elderly patients

O. Martha (RO)

14:30 - 15:00

Challenge the expert:

The best surgical approach for management of BPH is ...

14:30 - 14:35

Case presentation

D. Mun (AT)

14:35 - 14:45

Prostatic enucleation - the gold standard

S. Ahyai (AT)

14:45 - 14:55

Novel less invasive surgical therapy - the platinum standard

L. Lusuardi (AT)

14:55 - 15:00

Discussion

15:00 - 15:15

Coffee break and poster viewing

15:15 - 16:00

Pot pourri

Chairs: P. Nyirady (HU),
V. Kojović (SRB)

15:15 - 15:30

Central European Journal of Urology

B. Dybowski (PL)

15:30 - 15:45

Testosterone therapy in prostate cancer patients: safer than you thought!

Z. Kopa (HU)

15:45 - 16:00

Social media transforming medicine: get on board or become irrelevant

S. Ianiotescu (RO)

16:00 - 17:20

Country competition

Chairs: S. Shariat (AT), A. Stenzl (DE)
Judges: D. Bratus (SLO), P. Chlostá (PL),
M. Hora (CZ), S. Krause (AT),
O. Martha (RO), I. Minčík (SK),
P. Nyirady (HU), I. Tomašković (HR)

16:00 - 16:10

Austria: M. Pallauf
Neoadjuvant vs adjuvant
chemotherapy in upper tract
urothelial cancer

16:10 - 16:20

Croatia: B. Vrhovec
Comparison of patient-reported
outcomes (PROs) and patient-
reported experiences (PREs) for PNL
vs FURS in patients with stone
disease suitable for both surgical
modalities

16:20 - 16:30

Czech Rep.: V. Fiala
The role of neoadjuvant hormonal
treatment in cryptorchidism
management

16:30 - 16:40

Hungary: T. Fazekas
Different response to standard first
line treatments in BRCA positive
mCRPC – a meta-analysis

16:40 - 16:50

Poland: K. Gronostaj
The prognostic value of tumor
regression grades in muscle
invasive bladder cancer patients who
under-went neoadjuvant
chemotherapy followed by radical
cystectomy

16:50 - 17:00

Romania: C. Bulai
Narrow band imaging for non-
muscle invasive bladder cancer -
from better vision to oncologic
impact

17:00 - 17:10

Slovakia: V. Kovačik
Robot-assisted radical
prostatectomy - do we provide the
best possible treatment?

17:10 - 17:20

Slovenia: J. Jansa
Surgical treatment of renal mass
with robot-assisted partial
nephrectomy and the use of
intraoperative ultrasound and
flexible ureteroscopy.

Best 3 presentations will be given an
award. Best presentation 1.000 Euro,
second best 500 Euro, third best 300
Euro.

17:20 - 17:50

EAU lecture
From precision medicine to
precision surgery: how to use
medical technology to improve
oncology outcomes
A. Stenzl (DE)

17:50 - 18:00

**Award session: 3 best posters and
country competition winners**

18:00

Goodbye and farewell

**Prostate cancer: Treatment for biochemical recurrence (BCR) after
local therapy and for oligometastatic disease**

Place: Vienna (AT)

Date: 2nd April 2022

Chair A. Stenzl, Tübingen (DE)

10:45

**European School of Urology: A
unique possibility for urological
education**

A. Stenzl, Tübingen (DE)

10:50

**EAU Guidelines recommendations on
localized and locally advanced
prostate cancer**

A. Stenzl, Tübingen (DE)

11:05

Which imaging is necessary?

G. De Meerleer, Leuven (BE)

11:20

**Surgery or radiotherapy for
oligometastatic prostate cancer?**

A. Stenzl, Tübingen (DE)

11:35

**Adjuvant or early salvage
radiotherapy for biochemical
recurrent prostate cancer**

G. De Meerleer, Leuven (BE)

11:50

Interactive case discussion

S. Korn, Vienna (AT)

P. Rajwa, Vienna (AT)

12:15

Close

Special thanks to our sponsors!

Principal Sponsors



Gold Sponsors



Copper Sponsors



Silver Sponsors



Pop-Up Sponsors



Bronze Sponsors



Weitere Sponsoren





KEYTRUDA® beim adjuvanten Nierenzellkarzinom:

Die erste zugelassene Immuntherapie für die Behandlung geeigneter RCC-Patienten nach Nephrektomie.*

KEYTRUDA® beim metastasierten Nierenzellkarzinom:

Mit **KISPLYX®**** oder mit AXITINIB.***

* KEYTRUDA® ist als Monotherapie zur adjuvanten Behandlung des Nierenzellkarzinoms mit erhöhtem Rezidivrisiko nach Nephrektomie oder nach Nephrektomie und Resektion metastasierter Läsionen bei Erwachsenen zugelassen.

** KEYTRUDA® ist in Kombination mit Lenvatinib zur Erstlinienbehandlung des fortgeschrittenen Nierenzellkarzinoms bei Erwachsenen angezeigt.

*** KEYTRUDA® ist in Kombination mit AXITINIB zur Erstlinienbehandlung des fortgeschrittenen Nierenzellkarzinoms bei Erwachsenen angezeigt.

Bitte beachten Sie vor der Verordnung von KEYTRUDA® die vollständige, aktuelle Fachinformation.

Bitte beachten Sie vor der Verordnung von KEYTRUDA® und KISPLYX® die vollständigen, aktuellen Fachinformationen.
Fachkurzinformationen siehe Seite XY.